Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends
Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...
Yahoo13 days agoBDX
Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...
Yahoo13 days agoBDX
Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...
Yahoo14 days agoBDX
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
Yahoo15 days agoBDX
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Yahoo15 days agoBDX
What's Going On With Becton Dickinson Stock Wednesday?
FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.
Benzinga16 days agoBDX
FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson
Benzinga17 days agoBDX
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
Yahoo17 days agoBDX
Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?
Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
Yahoo18 days agoBDX
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.
Yahoo20 days agoBDX
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing
Becton Dickinsonâs buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returnsâget the latest Wall St view.
SeekingAlpha22 days agoBDX
Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.
Benzinga22 days agoBDX
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
Yahoo22 days agoBDX
RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190
RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.
Benzinga22 days agoBDX
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
Yahoo23 days agoBDX